These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 21177315

  • 1. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
    Li X, Huang Y, Fu X, Chen C, Zhang D, Yan L, Xie Y, Mao Y, Li Y.
    Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
    [Abstract] [Full Text] [Related]

  • 2. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JK.
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [Abstract] [Full Text] [Related]

  • 3. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
    Wang C, Tao W, Chen Q, Hu H, Wen XY, Han R.
    Prostate; 2010 Feb 01; 70(2):170-8. PubMed ID: 19760631
    [Abstract] [Full Text] [Related]

  • 4. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.
    Ntais C, Polycarpou A, Ioannidis JP.
    Cancer Epidemiol Biomarkers Prev; 2003 Jul 01; 12(7):618-24. PubMed ID: 12869400
    [Abstract] [Full Text] [Related]

  • 5. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S, Wiklund F, Adami HO, Bälter KA, Adolfsson J, Grönberg H.
    Cancer Res; 2006 Nov 15; 66(22):11077-83. PubMed ID: 17108148
    [Abstract] [Full Text] [Related]

  • 6. [V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer].
    Tong M, Jin YY, Li G, Liu SM, Ji CD.
    Zhonghua Nan Ke Xue; 2010 Nov 15; 16(11):990-3. PubMed ID: 21218640
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer].
    Liu JH, Li HW, Tong M, Li M, Na YQ.
    Zhonghua Yi Xue Za Zhi; 2004 Mar 02; 84(5):364-8. PubMed ID: 15061984
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men.
    Rajender S, Vijayalakshmi K, Pooja S, Madhavi S, Paul SF, Vettriselvi V, Shroff S, Singh L, Thangaraj K.
    J Androl; 2009 Mar 02; 30(6):703-10. PubMed ID: 19443907
    [Abstract] [Full Text] [Related]

  • 12. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT, Ursin G, Skinner EC, Dessissa T, Reichardt JK.
    Urol Oncol; 2005 Mar 02; 23(4):246-53. PubMed ID: 16018939
    [Abstract] [Full Text] [Related]

  • 13. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
    Scariano JK, Treat E, Alba F, Nelson H, Ness SA, Smith AY.
    Prostate; 2008 Dec 01; 68(16):1798-805. PubMed ID: 18780294
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
    Chang BL, Zheng SL, Isaacs SD, Turner AR, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J.
    Prostate; 2003 Jun 15; 56(1):37-44. PubMed ID: 12746845
    [Abstract] [Full Text] [Related]

  • 15. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
    Paz-y-Miño C, Witte T, Robles P, Llumipanta W, Díaz M, Arévalo M.
    Cancer Genet Cytogenet; 2009 Mar 15; 189(2):71-6. PubMed ID: 19215786
    [Abstract] [Full Text] [Related]

  • 16. Associations between the SRD5A2 gene V89L and TA repeat polymorphisms and breast cancer risk: a meta-analysis.
    Zhang D, Li Q, Qu HC, Yu T, Liu YR.
    Genet Mol Res; 2015 Aug 07; 14(3):9004-12. PubMed ID: 26345832
    [Abstract] [Full Text] [Related]

  • 17. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis.
    Ntais C, Polycarpou A, Ioannidis JP.
    Cancer Epidemiol Biomarkers Prev; 2003 Dec 07; 12(12):1395-402. PubMed ID: 14693728
    [Abstract] [Full Text] [Related]

  • 18. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
    Allen NE, Reichardt JK, Nguyen H, Key TJ.
    Cancer Epidemiol Biomarkers Prev; 2003 Jun 07; 12(6):578-81. PubMed ID: 12815006
    [Abstract] [Full Text] [Related]

  • 19. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
    Choubey VK, Sankhwar SN, Carlus SJ, Singh AN, Dalela D, Thangaraj K, Rajender S.
    Asian Pac J Cancer Prev; 2015 Jun 07; 16(3):1033-6. PubMed ID: 25735326
    [Abstract] [Full Text] [Related]

  • 20. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
    Lamharzi N, Johnson MM, Goodman G, Etzioni R, Weiss NS, Dightman DA, Barnett M, DiTommaso D, Chen C.
    Int J Cancer; 2003 Jul 01; 105(4):480-3. PubMed ID: 12712437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.